Korro Bio and Frequency Therapeutics Announce Merger Agreement

Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs


Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation


 Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026


Companies to host conference call today at 8:30 a.m. ET

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,United States ,Ram Aiyar ,Steve Colletti ,Vineet Agarwal ,Korro Bio ,Shelby Walker ,Todd Chappell ,Venkat Krishnamurthy ,Davidl Lucchino ,Stephanie Engels ,Alex Silverstein ,Piper Sandler ,Fidelity Management Research Company ,Exchange Commission ,Nasdaq ,Jp Morgan Securities ,Latham Watkins ,Verition Fund Management ,Korro Bio Inc ,Atlas Venture ,Frequency Therapeutics Inc ,Davis Polk Wardwell ,Goodwin Procter ,Frequency Therapeutics ,Surveyor Capital ,Cormorant Asset Management ,Qiming Venture Partners United States ,Venture Management ,Eventide Asset Management ,Fidelity Management ,Research Company ,Monashee Investment Management ,Sixty Degree Capital ,Frequency Therapeutic ,Chief Executive Officer ,Chief Financial Officer ,Chief Scientific Officer ,Senior Vice President ,Portfolio Planning ,General Counsel ,Jordan Baumhardt ,Korro Bio Board ,Multiple Sclerosis ,Current Report ,Davis Polk ,Adenosine Deaminase Acting ,Oligonucleotide Promoted Editing ,Securities Litigation Reform Act ,Frequency Therapeutic Form ,Securities Act ,Markets ,